Nanotechnology formulations for antibacterial free fatty acids and monoglycerides

Molecules

Volumn 21, Issue 3, 2016, Pages

  Jackman, Joshua A ^a   Yoon, Bo Kyeong ^a   Li, Danlin ^a   Cho, Nam Joon ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Antimicrobial lipid; Emulsion; Fatty acid; Hydrogel; Liposome; Monoglyceride; Nanotechnology; Solid lipid nanoparticle

Indexed keywords

ANTIINFECTIVE AGENT; EMULSION; FATTY ACID; HYDROGEL; LIPOSOME; MONOACYLGLYCEROL; NANOMATERIAL;

DRUG FORMULATION; EMULSION; HUMAN; HYDROGEL; MEDICINAL CHEMISTRY; NANOTECHNOLOGY; TRENDS;

ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; EMULSIONS; FATTY ACIDS, NONESTERIFIED; HUMANS; HYDROGELS; LIPOSOMES; MONOGLYCERIDES; NANOSTRUCTURES; NANOTECHNOLOGY;

EID: 84963699515     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21030305     Document Type: Review

References (84)

1. Laxminarayan, R.; Duse, A.; Wattal, C.; Zaidi, A.K.; Wertheim, H.F.; Sumpradit, N.; Vlieghe, E.; Hara, G.L.; Gould, I.M.; Goossens, H. Antibiotic Resistance-The Need for Global Solutions. Lancet Infect. Dis. 2013, 13, 1057-1098. [CrossRef]
2. Alanis, A.J. Resistance to Antibiotics: AreWe in the Post-antibiotic Era? Arch. Med. Res. 2005, 36, 697-705. [CrossRef] [PubMed]
3. Shlaes, D.M.; Sahm, D.; Opiela, C.; Spellberg, B. The FDA Reboot of Antibiotic Development. Antimicrob. Agents Chemother. 2013, 57, 4605-4607. [CrossRef] [PubMed]
4. Suda, K.J.; Hicks, L.A.; Roberts, R.M.; Hunkler, R.J.; Danziger, L.H. A National Evaluation of Antibiotic Expenditures by Healthcare Setting in the United States, 2009. J. Antimicrob. Chemother. 2013, 68, 715-718. [CrossRef] [PubMed]
5. Arias, C.A.; Murray, B.E. Antibiotic-resistant Bugs in the 21st Century-A Clinical Super-challenge. N. Engl. J. Med. 2009, 360, 439-443. [CrossRef] [PubMed]
6. Cooper, M.A.; Shlaes, D. Fix the Antibiotics Pipeline. Nature 2011, 472, 32. [CrossRef] [PubMed]
7. Priya, S.; Towse, A. New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options; Office of Health Economics: London, UK, 2011.
8. Laxminarayan, R.; Powers, J.H. Antibacterial R & D Incentives. Nat. Rev. Drug Discov. 2011, 10, 727-728. [PubMed]
9. Fauci, A.S.; Marston, H.D. The Perpetual Challenge of Antimicrobial Resistance. JAMA 2014, 311, 1853-1854. [CrossRef] [PubMed]
10. Nathan, C.; Cars, O. Antibiotic Resistance-Problems, Progress, and Prospects. N. Engl. J. Med. 2014, 371, 1761-1763. [CrossRef] [PubMed]
11. Outterson, K.; Powers, J.H.; Daniel, G.W.; McClellan, M.B. Repairing the Broken Market for Antibiotic Innovation. Health Aff. 2015, 34, 277-285. [CrossRef] [PubMed]
12. Mullard, A. 2014 FDA Drug Approvals. Nat. Rev. Drug Discov. 2015, 14, 77-81. [CrossRef] [PubMed]
13. Gao, W.; Thamphiwatana, S.; Angsantikul, P.; Zhang, L. Nanoparticle Approaches against Bacterial Infections. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2014, 6, 532-547. [CrossRef] [PubMed]
14. Ling, L.L.; Schneider, T.; Peoples, A.J.; Spoering, A.L.; Engels, I.; Conlon, B.P.; Mueller, A.; Schäberle, T.F.; Hughes, D.E.; Epstein, S. A New Antibiotic Kills Pathogens without Detectable Resistance. Nature 2015, 517, 455-459. [CrossRef] [PubMed]
15. Hancock, R.E.; Sahl, H.-G. Antimicrobial and Host-defense Peptides as New Anti-infective Therapeutic Strategies. Nat. Biotechnol. 2006, 24, 1551-1557. [CrossRef] [PubMed]
16. Afacan, N.J.; Yeung, A.T.; Pena, O.M.; Hancock, R.E. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr. Pharm. Des. 2012, 18, 807-819. [CrossRef] [PubMed]
17. Marr, A.K.; Gooderham, W.J.; Hancock, R.E. Antibacterial peptides for therapeutic use: Obstacles and realistic outlook. Curr. Opin. Pharmacol. 2006, 6, 468-472. [CrossRef] [PubMed]
18. Uhlig, T.; Kyprianou, T.; Martinelli, F.G.; Oppici, C.A.; Heiligers, D.; Hills, D.; Calvo, X.R.; Verhaert, P. The emergence of peptides in the pharmaceutical business: From exploration to exploitation. EuPA Open Proteom. 2014, 4, 58-69. [CrossRef]
19. Lehrer, R.I.; Ganz, T. Antimicrobial Peptides in Mammalian and Insect Host Defence. Curr. Opin. Immunol. 1999, 11, 23-27. [CrossRef]
20. Brown, K.L.; Hancock, R.E. Cationic Host Defense (antimicrobial) Peptides. Curr. Opin. Immunol. 2006, 18, 24-30. [CrossRef] [PubMed]
21. Thormar, H. Antibacterial Effects of Lipids: Historical Review (1881 to 1960). In Lipids and Essential Oils as Antimicrobial Agents; John Wiley & Sons, Ltd: Hoboken, NJ, USA, 2011; pp. 25-45.
22. Desbois, A.P.; Smith, V.J. Antibacterial Free Fatty Acids: Activities, Mechanisms of Action and Biotechnological Potential. Appl. Microbiol. Biotechnol. 2010, 85, 1629-1642. [CrossRef] [PubMed]
23. Desbois, A.P. Potential applications of antimicrobial fatty acids in medicine, agriculture and other industries. Recent Pat. Anti Infect. Drug Discov. 2012, 7, 111-122. [CrossRef]
24. Ramanathan, M.; Shrestha, L.K.; Mori, T.; Ji, Q.; Hill, J.P.; Ariga, K. Amphiphile nanoarchitectonics: From basic physical chemistry to advanced applications. Phys. Chem. Chem. Phys. 2013, 15, 10580-10611. [CrossRef] [PubMed]
25. Nakanishi, W.; Minami, K.; Shrestha, L.K.; Ji, Q.; Hill, J.P.; Ariga, K. Bioactive nanocarbon assemblies: Nanoarchitectonics and applications. Nano Today 2014, 9, 378-394. [CrossRef]
26. Ariga, K.; Ji, Q.; Nakanishi, W.; Hill, J.P.; Aono, M. Nanoarchitectonics: A new materials horizon for nanotechnology. Mater. Horiz. 2015, 2, 406-413. [CrossRef]
27. Ariga, K.; Li, J.; Fei, J.; Ji, Q.; Hill, J.P. Nanoarchitectonics for Dynamic Functional Materials from Atomic-/Molecular-Level Manipulation to Macroscopic Action. Adv. Mater. 2016, 28, 1251-1286. [CrossRef] [PubMed]
28. Nakatsuji, T.; Gallo, R.L. Antimicrobial Peptides: Old Molecules with New Ideas. J. Investig. Dermatol. 2011, 132, 887-895. [CrossRef] [PubMed]
29. Drake, D.R.; Brogden, K.A.; Dawson, D.V.; Wertz, P.W. Thematic Review Series: Skin Lipids. Antimicrobial Lipids at the Skin Surface. J. Lipid Res. 2008, 49, 4-11. [CrossRef] [PubMed]
30. Burtenshaw, J. Self-disinfection of the Skin: A Short Review and Some Original Observations. Br. Med. Bull. 1945, 3, 161-164. [PubMed]
31. Thormar, H.; Hilmarsson, H. The Role of Microbicidal Lipids in Host Defense against Pathogens and Their Potential as Therapeutic Agents. Chem. Phys. Lipids 2007, 150, 1-11. [CrossRef] [PubMed]
32. Fischer, C.L.; Blanchette, D.R.; Brogden, K.A.; Dawson, D.V.; Drake, D.R.; Hill, J.R.; Wertz, P.W. The Roles of Cutaneous Lipids in Host Defense. Biochim. Biophys. Acta 2014, 1841, 319-322. [CrossRef] [PubMed]
33. Aminov, R.I. A Brief History of the Antibiotic Era: Lessons Learned and Challenges for the Future. Front. Microbiol. 2010, 1, 134. [CrossRef] [PubMed]
34. Heerklotz, H. Interactions of Surfactants with Lipid Membranes. Q. Rev. Biophys. 2008, 41, 205-264. [CrossRef] [PubMed]
35. Hammer, K.A.; Carson, C.F. Antibacterial and Antifungal Activities of Essential Oils. In Lipids and Essential Oils as Antimicrobial Agents; John Wiley & Sons, Ltd: Hoboken, NJ, USA, 2011; pp. 255-306.
36. Kabara, J.; Vrable, R.; Jie, M.L.K. Antimicrobial Lipids: Natural and Synthetic Fatty Acids and Monoglycerides. Lipids 1977, 12, 753-759. [CrossRef] [PubMed]
37. Kabara, J.J. Structure-function relationships of surfactants as antimicrobial agents. J. Soc. Cosmet. Chem. 1978, 29, 733-741.
38. Kabara, J.J. Antimicrobial Agents Derived from Fatty Acids. J. Am. Oil Chem. Soc. 1984, 61, 397-403. [CrossRef]
39. Kabara, J.J.; Swieczkowski, D.M.; Conley, A.J.; Truant, J.P. Fatty Acids and Derivatives as Antimicrobial Agents. Antimicrob. Agents Chemother. 1972, 2, 23-28. [CrossRef] [PubMed]
40. Conley, A.J.; Kabara, J.J. Antimicrobial Action of Esters of Polyhydric Alcohols. Antimicrob. Agents Chemother. 1973, 4, 501-506. [CrossRef] [PubMed]
41. Kabara, J.J. GRAS Antimicrobial Agents for Cosmetic Products. J. Soc. Cosmet. Chem. 1980, 31, 1-10.
42. Nakatsuji, T.; Kao, M.C.; Fang, J.-Y.; Zouboulis, C.C.; Zhang, L.; Gallo, R.L.; Huang, C.-M. Antimicrobial Property of Lauric Acid against Propionibacterium acnes: Its Therapeutic Potential for Inflammatory Acne Vulgaris. J. Investig. Dermatol. 2009, 129, 2480-2488. [CrossRef] [PubMed]
43. Galbraith, H.; Miller, T.; Paton, A.; Thompson, J. Antibacterial activity of long chain fatty acids and the reversal with calcium, magnesium, ergocalciferol and cholesterol. J. Appl. Bacteriol. 1971, 34, 803-813. [CrossRef] [PubMed]
44. Nazari, M.; Kurdi, M.; Heerklotz, H. Classifying Surfactants with Respect to Their Effect on Lipid Membrane Order. Biophys. J. 2012, 102, 498-506. [CrossRef] [PubMed]
45. Bergsson, G.; Arnfinnsson, J.; Steingrímsson, Ó.; Thormar, H. Killing of Gram-positive cocci by Fatty Acids and Monoglycerides. APMIS 2001, 109, 670-678. [CrossRef] [PubMed]
46. Thid, D.; Benkoski, J.J.; Svedhem, S.; Kasemo, B.; Gold, J. DHA-induced changes of supported lipid membrane morphology. Langmuir 2007, 23, 5878-5881. [CrossRef] [PubMed]
47. Yoon, B.K.; Jackman, J.A.; Kim, M.C.; Cho, N.-J. Spectrum of membrane morphological responses to antibacterial fatty acids and related surfactants. Langmuir 2015, 31, 10223-10232. [CrossRef] [PubMed]
48. Vorum, H.; Brodersen, R.; Kragh-Hansen, U.; Pedersen, A.O. Solubility of Long-chain Fatty Acids in Phosphate Buffer at pH 7.4. Biochim. Biophys. Acta 1992, 1126, 135-142. [CrossRef]
49. Yang, D.; Pornpattananangkul, D.; Nakatsuji, T.; Chan, M.; Carson, D.; Huang, C.-M.; Zhang, L. The Antimicrobial Activity of Liposomal Lauric Acids against Propionibacterium acnes. Biomaterials 2009, 30, 6035-6040. [CrossRef] [PubMed]
50. Al-Adham, I.; Khalil, E.; Al-Hmoud, N.; Kierans, M.; Collier, P. Microemulsions are membrane-active, antimicrobial, self-preserving systems. J. Appl. Microbiol. 2000, 89, 32-39. [CrossRef] [PubMed]
51. Thormar, H.; Hilmarsson, H.; Bergsson, G. Stable concentrated emulsions of the 1-monoglyceride of capric acid (monocaprin) with microbicidal activities against the food-borne bacteria Campylobacter jejuni, Salmonella spp., and Escherichia coli. Appl. Environ. Microbiol. 2006, 72, 522-526. [CrossRef] [PubMed]
52. Fu, X.; Feng, F.; Huang, B. Physicochemical Characterization and Evaluation of a Microemulsion System for Antimicrobial Activity of Glycerol Monolaurate. Int. J. Pharm. 2006, 321, 171-175. [CrossRef] [PubMed]
53. Zhang, H.; Shen, Y.; Bao, Y.; He, Y.; Feng, F.; Zheng, X. Characterization and synergistic antimicrobial activities of food-grade dilution-stable microemulsions against Bacillus subtilis. Food Res. Int. 2008, 41, 495-499. [CrossRef]
54. Zhang, H.; Shen, Y.; Weng, P.; Zhao, G.; Feng, F.; Zheng, X. Antimicrobial activity of a food-grade fully dilutable microemulsion against Escherichia coli and Staphylococcus aureus. Int. J. Food Microbiol. 2009, 135, 211-215. [CrossRef] [PubMed]
55. Fu, X.; Zhang, M.; Huang, B.I.N.; Liu, J.U.N.; Hu, H.; Feng, F. Enhancement of Antimicrobial Activities by the Food-Grade Monolaurin Microemulsion System. J. Food Process Eng. 2009, 32, 104-111. [CrossRef]
56. Feng, F.; Zhang, H.; Sha, S.; Lu, Z.; Shen, Y.; Zheng, X. Characterization and Antimicrobial Evaluation of Dilution-Stable Microemulsions Against Stenotrophomonas maltrophilia. J. Dispers. Sci. Technol. 2009, 30, 503-509. [CrossRef]
57. Zhang, H.; Cui, Y.; Zhu, S.; Feng, F.; Zheng, X. Characterization and Antimicrobial Activity of a Pharmaceutical Microemulsion. Int. J. Pharm. 2010, 395, 154-160. [CrossRef] [PubMed]
58. Petra, Š.; Věra, K.; Iva, H.; Petr, H.; Zdeňka, K.; Leona, B. Formulation, Antibacterial Activity, and Cytotoxicity of 1-monoacylglycerol Microemulsions. Eur. J. Lipid Sci. Technol. 2014, 116, 448-457. [CrossRef]
59. Barenholz, Y.C. Doxil®-the First FDA-approved Nano-drug: Lessons Learned. J. Controll. Release 2012, 160, 117-134. [CrossRef] [PubMed]
60. Beaulac, C.; Clement-Major, S.; Hawari, J.; Lagacé, J. Eradication of Mucoid Pseudomonas aeruginosa with Fluid Liposome-encapsulated Tobramycin in an Animal Model of Chronic Pulmonary Infection. Antimicrob. Agents Chemother. 1996, 40, 665-669. [PubMed]
61. Beaulac, C.; Sachetelli, S.; Lagace, J. In-vitro bactericidal Efficacy of Sub-MIC Concentrations of Liposome-encapsulated Antibiotic against Gram-negative and Gram-positive Bacteria. J. Antimicrob. Chemother. 1998, 41, 35-41. [CrossRef] [PubMed]
62. Desjardins, A.; Chen, T.; Khalil, H.; Sayasith, K.; Lagace, J. Differential Behaviour of Fluid Liposomes toward Mammalian Epithelial Cells and Bacteria: Restriction of Fusion to Bacteria. J. Drug Target. 2002, 10, 47-54. [CrossRef] [PubMed]
63. Nikaido, H. Prevention of Drug Access to Bacterial Targets: Permeability Barriers and Active Efflux. Science 1994, 264, 382-388. [CrossRef] [PubMed]
64. Jung, S.W.; Thamphiwatana, S.; Zhang, L.; Obonyo, M. Mechanism of Antibacterial Activity of Liposomal Linolenic Acid against Helicobacter pylori. PLoS ONE 2015, 10, e0116519. [CrossRef] [PubMed]
65. Pornpattananangkul, D.; Fu, V.; Thamphiwatana, S.; Zhang, L.; Chen, M.; Vecchio, J.; Gao, W.; Huang, C.M.; Zhang, L. In vivo Treatment of Propionibacterium acnes Infection with Liposomal Lauric Acids. Adv. Healthc. Mater. 2013, 2, 1322-1328. [CrossRef] [PubMed]
66. Thamphiwatana, S.; Gao, W.; Obonyo, M.; Zhang, L. In vivo Treatment of Helicobacter pylori Infection with Liposomal Linolenic Acid Reduces Colonization and Ameliorates Inflammation. Proc. Natl. Acad. Sci. USA 2014, 111, 17600-17605. [CrossRef] [PubMed]
67. Huang, C.-M.; Chen, C.-H.; Pornpattananangkul, D.; Zhang, L.; Chan, M.; Hsieh, M.-F.; Zhang, L. Eradication of Drug Resistant Staphylococcus aureus by Liposomal Oleic Acids. Biomaterials 2011, 32, 214-221. [CrossRef] [PubMed]
68. Obonyo, M.; Zhang, L.; Thamphiwatana, S.; Pornpattananangkul, D.; Fu, V.; Zhang, L. Antibacterial Activities of Liposomal Linolenic Acids against Antibiotic-resistant Helicobacter pylori. Mol. Pharm. 2012, 9, 2677-2685. [CrossRef] [PubMed]
69. Chen, C.H.; Nakatsuji, T.; Zouboulis, C.C.; Zhang, L.; Huang, C.M. An Innate Bactericidal Oleic Acid Effective against Skin Infection of Methicillin-resistant Staphylococcus aureus: A Therapy Concordant with Evolutionary Medicine. J. Microbiol. Biotechnol. 2011, 21, 391-399. [PubMed]
70. Mbandi, E.; Brywig, M.; Shelef, L.A. Antilisterial Effects of Free Fatty Acids and Monolaurin in Beef Emulsions and Hot Dogs. Food Microbiol. 2004, 21, 815-818. [CrossRef]
71. Zhang, H.; Lu, Z.; Zhang, L.; Bao, Y.; Zhan, X.; Feng, F.; Zheng, X. Antifungal Activity of a Food-grade Dilution-stable Microemulsion against Aspergillus niger. Lett. Appl. Microbiol. 2008, 47, 445-450. [CrossRef] [PubMed]
72. Taylor, E.N.; Kummer, K.M.; Dyondi, D.; Webster, T.J.; Banerjee, R. Multi-scale Strategy to Eradicate Pseudomonas aeruginosa on Surfaces Using Solid Lipid Nanoparticles Loaded with Free Fatty Acids. Nanoscale 2014, 6, 825-832. [CrossRef] [PubMed]
73. Silva, E.L.; Carneiro, G.; de Araújo, L.A.; de Jesus, M.; Trindade, V.; Yoshida, M.I.; Oréfice, R.L.; de Macêdo Farias, L.; de Carvalho, M.A.R.; Santos, S.G.D. Solid Lipid Nanoparticles Loaded with Retinoic Acid and Lauric Acid as an Alternative for Topical Treatment of Acne Vulgaris. J. Nanosci. Nanotechnol. 2015, 15, 792-799. [CrossRef] [PubMed]
74. Ahmed, E.M. Hydrogel: Preparation, characterization, and applications. J. Adv. Res. 2013, 6, 105-121. [CrossRef] [PubMed]
75. Kristmundsdóttir, T.; Árnadóttir, S.G.; Bergsson, G.; Thormar, H. Development and evaluation of microbicidal hydrogels containing monoglyceride as the active ingredient. J. Pharm. Sci. 1999, 88, 1011-1015. [CrossRef] [PubMed]
76. Thormar, H.; Bergsson, G.; Gunnarsson, E.; Georgsson, G.; Witvrouw, M.; Steingrimsson, O.; de Clercq, E.; Kristmundsdóttir, T. Hydrogels containing monocaprin have potent microbicidal activities against sexually transmitted viruses and bacteria in vitro. Sex. Transm. Infect. 1999, 75, 181-185. [CrossRef] [PubMed]
77. Thorgeirsdottir, T.; Thormar, H.; Kristmundsdottir, T. The influence of formulation variables on stability and microbicidal activity of monoglyceride monocaprin. J. Drug Deliv. Sci. Technol. 2005, 15, 233-236. [CrossRef]
78. Kristmundsdóttir, T.; Sigurdsson, P.; Thormar, H. Effect of buffers on the properties of microbicidal hydrogels containing monoglyceride as the active ingredient. Drug Dev. Ind. Pharm. 2003, 29, 121-129. [CrossRef] [PubMed]
79. Thorgeirsdóttir, T.Ó.; Kjøniksen, A.-L.; Knudsen, K.D.; Kristmundsdóttir, T.; Nyström, B. Viscoelastic and structural properties of pharmaceutical hydrogels containing monocaprin. Eur. J. Pharm. Biopharm. 2005, 59, 333-342. [CrossRef] [PubMed]
80. Neyts, J.; Kristmundsdottir, T.; De Clercq, E.; Thormar, H. Hydrogels containing monocaprin prevent intravaginal and intracutaneous infections with HSV-2 in mice: Impact on the search for vaginal microbicides. J. Med. Virol. 2000, 61, 107-110. [CrossRef]
81. Skulason, S.; Holbrook, W.P.; Thormar, H.; Gunnarsson, G.B.; Kristmundsdottir, T. A study of the clinical activity of a gel combining monocaprin and doxycycline: A novel treatment for herpes labialis. J. Oral Pathol. Med. 2012, 41, 61-67. [CrossRef] [PubMed]
82. Duggan, A.; Atherton, J.; Cockayne, A.; Balsitis, M.; Evison, S.; Hale, T.; Hawkey, C.; Spiller, R. Clarification of the link between polyunsaturated fatty acids and Helicobacter pylori-associated duodenal ulcer disease: A dietary intervention study. Br. J. Nutr. 1997, 78, 515-522. [CrossRef] [PubMed]
83. Frieri, G.; Pimpo, M.T.; Palombieri, A.; Melideo, D.; Marcheggiano, A.; Caprilli, R.; D'Alessandro, A.; Seri, S. Polyunsaturated fatty acid dietary supplementation: An adjuvant approach to treatment of Helicobacter pylori infection. Nutr. Res. 2000, 20, 907-916. [CrossRef]
84. Dayrit, C.S. Coconut oil in health and disease: Its and monolaurin's potential as cure for HIV/AIDS. Indian Coconut J. 2000, 31, 19-24.